Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
about
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice.Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington diseaseMouse models of polyglutamine diseases: review and data table. Part ICalpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse modelAlterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.Mutant huntingtin impairs Ku70-mediated DNA repair.Ku70 alleviates neurodegeneration in Drosophila models of Huntington's diseaseLack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease.The effects of NMDA subunit composition on calcium influx and spike timing-dependent plasticity in striatal medium spiny neuronsCleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxiasBalance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin.Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington diseaseImpaired alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking and function by mutant huntingtin.Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's diseaseGlutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease.Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat.The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceTherapeutics development for triplet repeat expansion diseases.Neurotransmitter receptor expression and activity during neuronal differentiation of embryonal carcinoma and stem cells: from basic research towards clinical applications.The corticostriatal pathway in Huntington's disease.Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouseFull length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease.Effects of dopaminergic modulation on the integrative properties of the ventral striatal medium spiny neuron.Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatumEnhancement of NMDA receptor-mediated excitatory postsynaptic currents by gp120-treated macrophages: implications for HIV-1-associated neuropathology.Inositol 1,4,5-tripshosphate receptor, calcium signaling, and polyglutamine expansion disorders.Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of diseaseCell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex.Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Metaplasticity in human cortex.Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Blockade of NR2A-containing NMDA receptors induces Tau phosphorylation in rat hippocampal slices.N-methyl-D-aspartate (NMDA) receptor composition modulates dendritic spine morphology in striatal medium spiny neurons.Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.
P2860
Q24648260-F5393949-DF74-440D-BBBE-1575509781E0Q24657764-09FEB8F7-6273-42BD-99F8-5E4ACDF4ED41Q26853025-451ECBED-B298-4D6D-8174-8968FAD4CA18Q28265056-0B9BD0ED-C532-4147-BFA8-E9C10E319ACFQ33786465-0EF534CC-A939-4776-B21E-1DA73174CF80Q33840010-3CCA4473-26E4-4DAD-9183-A154FAB4BD3FQ34077884-920D1214-B848-4074-99F7-31FBE9341B6BQ34126315-070C7F02-54F6-47FD-BE0E-ACEB0839B01FQ34246880-5A7A69D9-D09C-4133-8098-73BC09546C62Q34780443-CC6574B2-B095-4497-8D2D-49D600E41756Q34981549-832ACEC7-446B-4DA8-8D02-3E0340F917BBQ35013054-B3CCF16C-B3A0-4564-A991-155DC2AEC251Q35146890-1C71EA34-4E98-41D8-A024-6ACA3E4839C0Q35311070-227168BC-0BC0-4116-8BF9-FDE6A741FAAFQ35828444-6239DD38-ECAE-4B57-BABC-40E6F0417B89Q36016647-6D64177C-B93C-423A-9631-67F48D424AE6Q36019780-12F5E79D-1E5D-46D1-BAA7-67263CE9765AQ36037085-BAE906A3-99F1-41F8-9FCA-AC4F5179FF8AQ36277195-7B8F309A-FF8B-4014-BC55-B2324242A491Q36548773-97CA02FB-0514-4386-BEE3-797294BF9F90Q36684263-CF4ABC14-F2DF-44DB-A3A7-465422E04EBAQ36713909-9851F8BE-9D69-454F-9010-861C2B05E978Q36861129-C95DC464-2DAF-4508-8374-443C20B0AE76Q36956907-59275A48-F862-4E82-A12C-1917207FF87EQ36959559-FCA7E79D-A82A-437C-A1D1-957FB5D1B012Q37000735-8D80D484-08FA-422F-965D-D54DD8C69642Q37086459-0BC5DAA8-11EC-4110-A02B-05783D0CACB2Q37201299-391546B2-5827-4687-AEC9-5297C58EFF8AQ37311202-3616B2AD-70B9-4269-BD18-4CC18FFAD6A8Q37313511-ACFF7ABE-C35F-4381-A539-895BC481D504Q37607024-E96FFF1C-1B7A-4F86-B4F4-5566B6B7962CQ37930190-C4D9C489-9B4D-40D5-BFF8-58D71C4EC703Q38195271-A12ED5F5-2048-4BA5-9C2C-B4224E803072Q38603960-8DFC926E-8087-40EB-9106-FC20C8CD9F69Q38928777-A19966B9-29F8-43A1-81ED-121F841A8D70Q40700702-39CDC59A-E22B-417B-B699-4BB9931A56F3Q41927894-7470F3F0-5986-4C3D-88FF-60133663BF63Q45292629-9CE0444B-D958-47B6-9C22-35B9852711F6Q45306738-52A99BE6-6C96-4C50-8609-A80A9E4E8631Q47786283-EA8B8374-19A3-41F2-AD56-9DD300126CFB
P2860
Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Enhanced striatal NR2B-contain ...... e model of Huntington disease.
@en
Enhanced striatal NR2B-contain ...... e model of Huntington disease.
@nl
type
label
Enhanced striatal NR2B-contain ...... e model of Huntington disease.
@en
Enhanced striatal NR2B-contain ...... e model of Huntington disease.
@nl
prefLabel
Enhanced striatal NR2B-contain ...... e model of Huntington disease.
@en
Enhanced striatal NR2B-contain ...... e model of Huntington disease.
@nl
P2860
P356
P1476
Enhanced striatal NR2B-contain ...... e model of Huntington disease.
@en
P2093
Timothy H Murphy
P2860
P304
P356
10.1152/JN.00308.2004
P407
P577
2004-07-07T00:00:00Z